Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06902246 · ClinicalTrials.gov registry record · Phase 2
Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma
A Phase 2 study of Hepatocellular Carcinoma and Unresectable Hepatocellular Carcinoma, sponsored by University of Miami.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06902246 is a Phase 2 study of Hepatocellular Carcinoma and Unresectable Hepatocellular Carcinoma that is actively recruiting participants, run by University of Miami. The registered enrollment target is 30 participants, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06902246, a Phase 2 study of Hepatocellular Carcinoma and Unresectable Hepatocellular Carcinoma, is actively recruiting participants, sponsored by University of Miami.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the effects that Regorafenib in combination with Yttrium-90 (Y-90) radioembolization has on patients with unresectable hepatocellular carcinoma.
Conditions Studied
Interventions
- DRUG Regorafenib
- RADIATION TheraSphere™ Yttrium-90 Trans-Arterial Radioembolization
Study Locations (1)
Florida
- University of Miami - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-01-05 |
| Est. Completion | 2031-01-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06902246
The ClinicalTrials.gov registry entry for NCT06902246 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (88% lower). The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Regorafenib is the first listed.
NCT06902246 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT06902246 about?
NCT06902246 is a clinical study titled "Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma". The purpose of this study is to determine the effects that Regorafenib in combination with Yttrium-90 (Y-90) radioembolization has on patients with unresectable hepatocellular carcinoma.
What is the current status of trial NCT06902246?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2026-01-05. Estimated completion is 2031-01-05.
What conditions does trial NCT06902246 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma.
What interventions are being tested in trial NCT06902246?
The interventions under investigation include: Regorafenib (DRUG), TheraSphere™ Yttrium-90 Trans-Arterial Radioembolization (RADIATION).
Who is sponsoring clinical trial NCT06902246?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06902246 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Combination of TATE and PD-1 Inhibitor in Liver Cancer
RECRUITING · Phase 2
-
Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
RECRUITING · Phase 2
-
A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer
RECRUITING · Phase 2
-
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis
RECRUITING · Phase 2
-
Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.